Jiacheng Bi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiacheng Bi has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Xiaochun Wan
State Key Laboratory of Tea Plant Germplasm Innovation and Resource Utilization, Anhui Agricultural University , Hefei, Anhui 230036
9 shared publications - Zhigang Tian
University of Science and Technology of China
9 shared publications Chaoyue Zheng
The CAS Key Laboratory of Quantitative Engineering Biology Shenzhen Institute of Synthetic Biology Shenzhen Institute of Advanced Technology Chinese Academy of Sciences Shenzhen 518055 P. R. China
7 shared publicationsChen Huang
The CAS Key Laboratory of Quantitative Engineering Biology Shenzhen Institute of Synthetic Biology Shenzhen Institute of Advanced Technology Chinese Academy of Sciences Shenzhen 518055 P. R. China
4 shared publicationsLulu Cui
Shenzhen Laboratory of Fully Human Antibody Engineering, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, People's Republic of China
4 shared publicationsHaiming Wei
Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui, China
3 shared publications
Latest Publications
- 18 July 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 186, 117160
Human NKG2C+ adaptive NK cells for Cancer immunotherapy
- 18 July 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 186, 117160
Human NKG2C+ adaptive NK cells for Cancer immunotherapy
- 10 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105333
Cytokine-based NK cell engineering for cancer immunotherapy
- 10 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105333
Cytokine-based NK cell engineering for cancer immunotherapy
- Open Access
- 24 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e010841
Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma
Background: Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood. Methods: To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we integrated allograft tumor models with bulk and single-cell RNA sequencing analyses. Biochemical assays were performed to investigate the mechanisms underlying Nrf2 inhibition in immune resistance. The combined activity of Nrf2 inhibition with anti-programmed death-1 (PD-1) antibody and CAR-T cell therapy was also explored in vivo. Results: We show that brusatol (BRU), a specific inhibitor of Nrf2, an emerging regulator of the tumor immune microenvironment, potentiates antitumor immunity in HCC mouse models. Mechanistically, inhibition of Nrf2 downregulates surface programmed death ligand-1 (PD-L1) expression via transcriptional repression in tumor cells, while upregulating major histocompatibility complex (MHC)-I expression via nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Nrf2 in tumor cells enhances the activation of immune-related signaling pathways and promotes CD8 + T-cell infiltration into tumor tissues. Furthermore, inhibition of Nrf2 with BRU significantly enhances the efficacy of PD-1 antibody and CAR-T cells against HCC in vivo, indicating that therapeutic targeting of Nrf2 in HCC cells sensitizes them to ICIs and CAR-T immunotherapies. Conclusions: Our findings offer a novel strategy to enhance HCC immunotherapy by blocking Nrf2, which has the potential to address the low response rates observed with current HCC immunotherapies.
- 24 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e010841
Open AccessTargeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma
Background: Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood. Methods: To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we integrated allograft tumor models with bulk and single-cell RNA sequencing analyses. Biochemical assays were performed to investigate the mechanisms underlying Nrf2 inhibition in immune resistance. The combined activity of Nrf2 inhibition with anti-programmed death-1 (PD-1) antibody and CAR-T cell therapy was also explored in vivo. Results: We show that brusatol (BRU), a specific inhibitor of Nrf2, an emerging regulator of the tumor immune microenvironment, potentiates antitumor immunity in HCC mouse models. Mechanistically, inhibition of Nrf2 downregulates surface programmed death ligand-1 (PD-L1) expression via transcriptional repression in tumor cells, while upregulating major histocompatibility complex (MHC)-I expression via nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Nrf2 in tumor cells enhances the activation of immune-related signaling pathways and promotes CD8 + T-cell infiltration into tumor tissues. Furthermore, inhibition of Nrf2 with BRU significantly enhances the efficacy of PD-1 antibody and CAR-T cells against HCC in vivo, indicating that therapeutic targeting of Nrf2 in HCC cells sensitizes them to ICIs and CAR-T immunotherapies. Conclusions: Our findings offer a novel strategy to enhance HCC immunotherapy by blocking Nrf2, which has the potential to address the low response rates observed with current HCC immunotherapies.
- 22 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 219, 105141
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
- 22 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 219, 105141
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
- 7 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 847-859
TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis
PD-L1 serves as the ligand for the immune inhibitory checkpoint protein PD-1, and its expression in tumors can be induced by interferon-γ (IFN-γ), leading to immune evasion. While JAK/STAT signaling is known to mediate IFN-γ-induced PD-L1 expression, the mechanisms governing the negative regulation of PD-L1 in response to IFN-γ remain largely unclear. Here, we find that the E3 ubiquitin ligase TRIM11 is significantly stabilized to block the induction of PD-L1 upon treatment with IFN-γ. TRIM11 functions as a tumor suppressor by enhancing cytotoxic T lymphocyte (CTL) activity and potentiating antitumor immunity within the local tumor microenvironment. Mechanistically, TRIM11 and JAK1 interact and mutually regulate each other through post-translational modifications in response to IFN-γ stimulation. JAK1 phosphorylates TRIM11, leading to its stabilization and activation by reducing K48-linked polyubiquitination and subsequent proteasomal degradation. Meanwhile, TRIM11 inhibits JAK1 through K63-linked polyubiquitination, thereby suppressing downstream JAK/STAT signaling, particularly reducing PD-L1 expression. This enhances CTL activity and bolsters antitumor effects in the presence of IFN-γ. Moreover, low expression of TRIM11, IFN-γ, and CD8+ T cells correlates with poor prognosis in patients, while TRIM11 expression levels could predict sensitivity to immune checkpoint blockade therapy. These findings define a role for the TRIM11/JAK1 axis in IFN-γ-induced PD-L1 expression, suggesting its potential as a therapeutic target to enhance cancer immunotherapy.
- 7 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 847-859
TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis
PD-L1 serves as the ligand for the immune inhibitory checkpoint protein PD-1, and its expression in tumors can be induced by interferon-γ (IFN-γ), leading to immune evasion. While JAK/STAT signaling is known to mediate IFN-γ-induced PD-L1 expression, the mechanisms governing the negative regulation of PD-L1 in response to IFN-γ remain largely unclear. Here, we find that the E3 ubiquitin ligase TRIM11 is significantly stabilized to block the induction of PD-L1 upon treatment with IFN-γ. TRIM11 functions as a tumor suppressor by enhancing cytotoxic T lymphocyte (CTL) activity and potentiating antitumor immunity within the local tumor microenvironment. Mechanistically, TRIM11 and JAK1 interact and mutually regulate each other through post-translational modifications in response to IFN-γ stimulation. JAK1 phosphorylates TRIM11, leading to its stabilization and activation by reducing K48-linked polyubiquitination and subsequent proteasomal degradation. Meanwhile, TRIM11 inhibits JAK1 through K63-linked polyubiquitination, thereby suppressing downstream JAK/STAT signaling, particularly reducing PD-L1 expression. This enhances CTL activity and bolsters antitumor effects in the presence of IFN-γ. Moreover, low expression of TRIM11, IFN-γ, and CD8+ T cells correlates with poor prognosis in patients, while TRIM11 expression levels could predict sensitivity to immune checkpoint blockade therapy. These findings define a role for the TRIM11/JAK1 axis in IFN-γ-induced PD-L1 expression, suggesting its potential as a therapeutic target to enhance cancer immunotherapy.
- 28 September 2024
- Published by Springer Nature in Frontiers of Medicine
- Vol. 18 (5) , 763-777
Intracellular checkpoints for NK cell cancer immunotherapy
Natural killer (NK) cells are key innate immune lymphocytes, which play important roles against tumors. However, tumor-infiltrating NK cells are always hypofunctional/exhaustive. On the one hand, this state is contributed by context-dependent interactions between inhibitory NK cell checkpoint receptors and their ligands, which usually vary in different tumor types and stages during tumor development. On the other hand, the inhibitory functions of intracellular checkpoint molecules of NK cells are more similar across different tumor types, representing common mechanisms limiting the potential of NK cell therapy. In this review, representative NK cell intracellular checkpoint molecules in different aspects of NK cell biology were reviewed, and therapeutic potentials were discussed by targeting these molecules to promote antitumor NK cell therapy.
- 28 September 2024
- Published by Springer Nature in Frontiers of Medicine
- Vol. 18 (5) , 763-777
Intracellular checkpoints for NK cell cancer immunotherapy
Natural killer (NK) cells are key innate immune lymphocytes, which play important roles against tumors. However, tumor-infiltrating NK cells are always hypofunctional/exhaustive. On the one hand, this state is contributed by context-dependent interactions between inhibitory NK cell checkpoint receptors and their ligands, which usually vary in different tumor types and stages during tumor development. On the other hand, the inhibitory functions of intracellular checkpoint molecules of NK cells are more similar across different tumor types, representing common mechanisms limiting the potential of NK cell therapy. In this review, representative NK cell intracellular checkpoint molecules in different aspects of NK cell biology were reviewed, and therapeutic potentials were discussed by targeting these molecules to promote antitumor NK cell therapy.
- 27 September 2023
- Published by Wiley in Immunology
- Vol. 171 (1) , 60-76
Suppression of protein quality control system by TRIM30a sensitises tumour cells to NK cell‐mediated immune surveillance
Tumorigenesis entails circumventing cell-intrinsic regulatory mechanisms while avoiding extrinsic immune surveillance and other host defence systems. Nevertheless, how tumour cells ' ability to eliminate misfolded proteins affects immune surveillance remains poorly understood. In this study, we find that overexpression of murine tripartite motif-containing protein 30a (TRIM30a) sensitises tumour cells to natural killer (NK) cells-mediated cytolysis. TRIM30a has no effect on tumour cell proliferation or apoptosis in vitro. However, TRIM30a-overexpressing tumour cells grow substantially slower than control tumour cells in immune-competent mice but not in NK-depleted mice. Mechanistically, TRIM30a overexpression impedes the clearance of misfolded protein and increases the production of reactive oxygen species induced by proteotoxic stress, implying that TRIM30a impairs protein quality control (PQC) systems in tumour cells. Furthermore, TRIM30a reduces expression of genes encoding proteasome subunits and antioxidant proteins. Our study demonstrates that TRIM30a is a potential tumour suppressor and immune modulator that promotes tumour cytolysis by NK cells, and suggests that an enhanced PQC and antioxidant capacity is an integral part of the immune escape mechanism during tumorigenesis.
- 27 September 2023
- Published by Wiley in Immunology
- Vol. 171 (1) , 60-76
Suppression of protein quality control system by TRIM30a sensitises tumour cells to NK cell‐mediated immune surveillance
Tumorigenesis entails circumventing cell-intrinsic regulatory mechanisms while avoiding extrinsic immune surveillance and other host defence systems. Nevertheless, how tumour cells ' ability to eliminate misfolded proteins affects immune surveillance remains poorly understood. In this study, we find that overexpression of murine tripartite motif-containing protein 30a (TRIM30a) sensitises tumour cells to natural killer (NK) cells-mediated cytolysis. TRIM30a has no effect on tumour cell proliferation or apoptosis in vitro. However, TRIM30a-overexpressing tumour cells grow substantially slower than control tumour cells in immune-competent mice but not in NK-depleted mice. Mechanistically, TRIM30a overexpression impedes the clearance of misfolded protein and increases the production of reactive oxygen species induced by proteotoxic stress, implying that TRIM30a impairs protein quality control (PQC) systems in tumour cells. Furthermore, TRIM30a reduces expression of genes encoding proteasome subunits and antioxidant proteins. Our study demonstrates that TRIM30a is a potential tumour suppressor and immune modulator that promotes tumour cytolysis by NK cells, and suggests that an enhanced PQC and antioxidant capacity is an integral part of the immune escape mechanism during tumorigenesis.
- Open Access
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells
Natural killer (NK) cells not only are innate effector lymphocytes that directly participate in tumor surveillance but are also essential helpers in the antitumor CD8+ T‐cell response. However, the molecular mechanisms and potential checkpoints regulating NK cell helper functions remain elusive. Here, it is shown that the T‐bet/Eomes‐IFN‐γ axis in NK cells is essential for CD8+ T cell‐dependent tumor control, whereas T‐bet‐dependent NK cell effector functions are required for an optimal response to anti‐PD‐L1 immunotherapy. Importantly, NK cell‐expressed TIPE2 (tumor necrosis factor‐alpha‐induced protein‐8 like‐2) represents a checkpoint molecule for NK cell helper function, since Tipe2 deletion in NK cells not only enhances NK‐intrinsic antitumor activity but also indirectly improves the antitumor CD8+ T cell response by promoting T‐bet/Eomes‐dependent NK cell effector functions. These studies thus reveal TIPE2 as a checkpoint for NK cell helper function, whose targeting might boost the antitumor T cell response in addition to T cell‐based immunotherapy.
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Open AccessCheckpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells
Natural killer (NK) cells not only are innate effector lymphocytes that directly participate in tumor surveillance but are also essential helpers in the antitumor CD8+ T‐cell response. However, the molecular mechanisms and potential checkpoints regulating NK cell helper functions remain elusive. Here, it is shown that the T‐bet/Eomes‐IFN‐γ axis in NK cells is essential for CD8+ T cell‐dependent tumor control, whereas T‐bet‐dependent NK cell effector functions are required for an optimal response to anti‐PD‐L1 immunotherapy. Importantly, NK cell‐expressed TIPE2 (tumor necrosis factor‐alpha‐induced protein‐8 like‐2) represents a checkpoint molecule for NK cell helper function, since Tipe2 deletion in NK cells not only enhances NK‐intrinsic antitumor activity but also indirectly improves the antitumor CD8+ T cell response by promoting T‐bet/Eomes‐dependent NK cell effector functions. These studies thus reveal TIPE2 as a checkpoint for NK cell helper function, whose targeting might boost the antitumor T cell response in addition to T cell‐based immunotherapy.
- Open Access
- 1 February 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (2) , e006002
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
Background: To enhance the efficacy of adoptive NK cell therapy against solid tumors, NK cells must be modified to resist exhaustion in the tumor microenvironment (TME). However, the molecular checkpoint underlying NK cell exhaustion in the TME remains elusive. Methods: We analyzed the correlation between TIPE2 expression and NK cell functional exhaustion in the TME both in humans and mice by single-cell transcriptomic analysis and by using gene reporter mice. We investigated the effects of TIPE2 deletion on adoptively transferred NK cell therapy against cancers by using NK cells from NK-specific Tipe2-deficient mice or peripheral blood-derived or induced pluripotent stem cell (iPSC)-derived human NK cells with TIPE2 deletion by CRISPR/Cas9. We also investigated the potential synergy of double deletion of TIPE2 and another checkpoint molecule, CISH. Results: By single-cell transcriptomic analysis and by using gene reporter mice, we found that TIPE2 expression correlated with NK cell exhaustion in the TME both in humans and mice and that the TIPE2 high NK cell subset correlated with poorer survival of tumor patients. TIPE2 deletion promoted the antitumor activity of adoptively transferred mouse NK cells and adoptively transferred human NK cells, either derived from peripheral blood or differentiated from iPSCs. TIPE2 deletion rendered NK cells with elevated capacities for tumor infiltration and effector functions. TIPE2 deletion also synergized with CISH deletion to further improve antitumor activity in vivo. Conclusions: This study highlighted TIPE2 targeting as a promising approach for enhancing adoptive NK cell therapy against solid tumors.
- 1 February 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (2) , e006002
Open AccessTIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
Background: To enhance the efficacy of adoptive NK cell therapy against solid tumors, NK cells must be modified to resist exhaustion in the tumor microenvironment (TME). However, the molecular checkpoint underlying NK cell exhaustion in the TME remains elusive. Methods: We analyzed the correlation between TIPE2 expression and NK cell functional exhaustion in the TME both in humans and mice by single-cell transcriptomic analysis and by using gene reporter mice. We investigated the effects of TIPE2 deletion on adoptively transferred NK cell therapy against cancers by using NK cells from NK-specific Tipe2-deficient mice or peripheral blood-derived or induced pluripotent stem cell (iPSC)-derived human NK cells with TIPE2 deletion by CRISPR/Cas9. We also investigated the potential synergy of double deletion of TIPE2 and another checkpoint molecule, CISH. Results: By single-cell transcriptomic analysis and by using gene reporter mice, we found that TIPE2 expression correlated with NK cell exhaustion in the TME both in humans and mice and that the TIPE2 high NK cell subset correlated with poorer survival of tumor patients. TIPE2 deletion promoted the antitumor activity of adoptively transferred mouse NK cells and adoptively transferred human NK cells, either derived from peripheral blood or differentiated from iPSCs. TIPE2 deletion rendered NK cells with elevated capacities for tumor infiltration and effector functions. TIPE2 deletion also synergized with CISH deletion to further improve antitumor activity in vivo. Conclusions: This study highlighted TIPE2 targeting as a promising approach for enhancing adoptive NK cell therapy against solid tumors.
- Open Access
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1084109
Prospects for NK-based immunotherapy of chronic HBV infection
Effective and long-term treatment is required for controlling chronic Hepatitis B Virus (HBV) infection. Natural killer (NK) cells are antiviral innate lymphocytes and represent an essential arm of current immunotherapy. In chronic HBV (CHB), NK cells display altered changes in phenotypes and functions, but preserve antiviral activity, especially for cytolytic activity. On the other hand, NK cells might also cause liver injury in the disease. NK -based immunotherapy, including adoptive NK cell therapy and NK -based checkpoint inhibition, could potentially exploit the antiviral aspect of NK cells for controlling CHB infection while preventing liver tissue damage. Here, we review recent progress in NK cell biology under the context of CHB infection, and discuss potential NK -based immunotherapy strategies for the disease.
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1084109
Open AccessProspects for NK-based immunotherapy of chronic HBV infection
Effective and long-term treatment is required for controlling chronic Hepatitis B Virus (HBV) infection. Natural killer (NK) cells are antiviral innate lymphocytes and represent an essential arm of current immunotherapy. In chronic HBV (CHB), NK cells display altered changes in phenotypes and functions, but preserve antiviral activity, especially for cytolytic activity. On the other hand, NK cells might also cause liver injury in the disease. NK -based immunotherapy, including adoptive NK cell therapy and NK -based checkpoint inhibition, could potentially exploit the antiviral aspect of NK cells for controlling CHB infection while preventing liver tissue damage. Here, we review recent progress in NK cell biology under the context of CHB infection, and discuss potential NK -based immunotherapy strategies for the disease.